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Abstract

Glycine acts as an inhibitory neurotransmitter and a co-agonist of NMDAR at the
glutamatergic synapses. Termination of glycinergic neurotransmission is achieved by
glycine transporter 1 (GlyT1) and glycine transporter (GlyT2). Both transporters are
expressed in the spinal cord, brainstem and cerebellum, but GlyT1 is also expressed in
the retina and the forebrain.

Previous studies have described the role and cyto-

architecture of GlyT1 in the caudal areas of the brain and retina, but not in the
structures of the forebrain. Based on our preliminary data, GlyT1 is highly expressed in
the thalamus, an area involved in sensory and motor signal relay.

The function,

mechanism and the cell type expressing GlyT1 in this area are poorly studied and
deserves to be studied. Preliminary results demonstrate that GlyT1 immunoreactivity is
expressed in neurons rather than glial cells. However, the characterization of the
neurons expressing GlyT1 remains unknown. Due to the dual phenotype of GABAergic
and glycinergic neurons in other regions of the brain, it is hypothesized that the cells
expressing GlyT1 in the thalamus are GABAergic. To address this question, we
performed conventional immunohistochemistry, fluorescent and viral tracing, and
transgenic mice models. Given the expression of GlyT1 in areas of the thalamus, these
results suggest a better characterization of the location of GyT1 and suggest that it
might have a different role aside the inhibitory role of the caudal structures of the brain.
These findings will help understand the glycinergic kinetics and the overall role and
function of GlyT1.
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Chapter 1
Introduction

1.1 Cell Communication in the Central Nervous System
During the past few centuries, the central nervous system (CNS) has been
studied by different approaches in order to understand its interactions, mechanisms,
and functions. Nevertheless, it has not been possible to fully elucidate how it regulates
the body functions because of the complexity of its millions of connections. Hundreds of
questions are yet to be answered and joint efforts are still required to learn more about
the mysteries of the CNS.
Just as every living organism finds ways of maintaining homeostasis for various
mechanisms and processes, the CNS has to maintain a chemical balance in order to
function properly. In the same manner within the neurotransmission process,
neurotransmitters levels have to be regulated by specific proteins known as
neurotransmitter transporters.
Neural communication can be compared to a follow-up letter that contains a
specific message, where the writer sends the message in an enclosed envelope. The
sender has to deliver the message with the exact content in order to be comprehended
by the recipient. The message has to be clear, organized and sent on time;
consequently, the recipient will receive it and understand the message. The same
concept is applied for neural communication. There are presynaptic and postsynaptic
neurons, which act as the sender and the recipient of the message, respectively. The
neurotransmitters, which serve as the message, are stored in synaptic vesicles. The
regulation of the message is a critical step during cellular communication. Vesicles and
1

neurotransmitter transporters are in charge of controlling and regulating the
aforementioned process. In nature, glycine is one of the chemical messengers that
transmits signals in the CNS (Zafra and Giménez, 2008).

1. 2 Glycine
1. 2. 1 Glycine: Biosynthesis and Degradation
Glycine is the simplest amino acid. It has one amino group, one carboxyl group
and two hydrogen atoms bound to one carbon atom. It plays several important functions
in metabolic regulation, anti-oxidative reactions and neurological function (Wang et al.,
2013). In all mammals and other vertebrates, glycine acts a precursor for
macromolecules and furnishes all the nitrogen atoms of purines (Nelson and Cox,
2005).
Several biological pathways yield on the production of this amino acid. Glycine is
synthesized

from

different

amino

acids

such

as

serine

(via

serine

hydroxymethyltransferase (SHMT)), threonine, choline and hydroxyproline involving the
liver and kidneys (Wang et al., 2013). Glycine biosynthesis and degradation are crucial
processes. The glycine cleavage system (GCS, also called glycine synthase) is the
principal enzyme that degrades glycine in mammals. It is worth mentioning that a
genetic defect in the GCS might lead to a congenital metabolic disease known as
glycine encephalopathy or non-ketotic hyperglycinemia. The accumulation of the amino
acid in the fluids and tissues of the body, especially in the cerebrospinal fluid,
characterize this rare metabolic disorder. Patients with this disease present severe brain
malformation and neurological symptoms such as seizures, hypotonia, intellectual
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disability, and myoclonic jerking (Applegarth and Toone, 2006). An important point to
consider is that these serious symptoms are not manifested in any other known amino
acid metabolic disorders; demonstrating that glycine has an essential and indispensable
role in the brain development and function (Sato, 2018).

1. 2. 2 Glycine as a Neurotransmitter
It was not until 1965, when Aprison and Werman proposed and described, for the
first time, the presence of glycine as neurotransmitter in the spinal cord of cats (Aprison
and Werman, 1965). Five years later, Shank and Aprison demonstrated that glycine
could be synthesized by neurons. Simultaneously, Hopkin and Neal published their
studies revealing that glycine was released from spinal cord slices after proper
stimulation (Hopkin and Neal, 1970). Since then, glycine has been identified and
recognized as a neurotransmitter (Bowery and Smart, 2006). In recent years, glycine
has been considered as the major inhibitory neurotransmitter in the posterior areas of
the vertebrate central nervous system, especially in the brainstem, spinal cord (Aprison
and Werman, 1965) and retina (Aragón and López-Corcuera, 2003, Vitanova et al.,
2004). Glycine is involved in the coordination of reflex responses (muscle tone balance),
processing of sensory signals, and sensation of pain (Zafra and Giménez, 2008). The
presence of glycine in these caudal areas of the CNS has been studied and
established. However, glycine has also been discovered in other regions of the brain
such as the forebrain, where its function has not been fully addressed yet. In these
areas, glycine may play a different function besides its well-known inhibitory role
(Hernandes and Troncone, 2009).
3

1. 3 Glycinergic Synapse, Receptors and Transporters
1. 3. 1 Glycinergic Neurotransmission
The glycinergic neurotransmission needs to follow a series of steps. First, the
storage of the molecule in the synaptic vesicles from the presynaptic neuron, neuron
depolarization, glycine-release in the synaptic cleft and its binding to the receptors (Neal
and Pickles, 1969)
In the CNS, glycine plays two physiological functions. It is involved in the
inhibitory and excitatory synapse [illustration 1].

Illustration 1. Neurotransmission at the glycinergic synapses. Schematic
representation of the glycinergic inhibitory (left) and excitatory (right) synapse.
The legend shows the representation of each protein in the diagram. Adapted
from Harvey and Yee, 2013.
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Glycinergic Inhibitory Neurotransmission
Glycine is stored in the synaptic vesicles. Upon depolarization, it is released by
the Ca2+-mediated influx to the synaptic cleft. Glycine binds to specific glycine receptors
(GlyRs). The GlyRs are located in patches in the postsynaptic neuron and they are
ligand-gated chloride channels composed of α and β subunits (Betz and Laube, 2006;
Lynch, 2009). The binding of glycine within the ionotropic GlyRs allows the pore of the
receptors to open and Cl- ions to passively diffuse across the cell membrane of the
postsynaptic neuron. Therefore, the intracellular Cl- concentration increases and
changes the postsynaptic membrane potential leading a neural hyperpolarization. This
inhibition of action potentials prevents depolarization and neuronal firing induced by
excitatory neurotransmitters (Stein and Nicoll, 2013). However, the glycinergic
transmission does not stop at this point. Glycine has to return to the basal levels (Zafra
and Giménez, 2008) and be prepared for the next required cycle. Glycine transporters
(GlyTs) are plasma membrane transporters that terminate glycine signaling. These
proteins regulate the extracellular concentration of glycine and facilitate the termination
of glycinergic neurotransmission at the synaptic cleft.
In the mammalian-mature brain stem and spinal cord, inhibitory-glycinergic
transmission has a well-established role in the regulation of motor control and reflex
responses (Legendre, 2001). Glycine transmission focuses on vision (Vitanova et al.,
2004), audition (Friauf et al., 1997), cardiovascular (Hildreth and Goodchild, 2010) and
respiratory functions (Fortuna, Kugler and Hulsmann, 2018)

5

Glycinergic Excitatory Neurotransmission
Glycine not only participates under inhibitory neurotransmission; it is also
involved in glutamatergic neurotransmission. Glutamate is the primary excitatory
neurotransmitter in the CNS, where it plays a critical role in synaptic plasticity. At the
excitatory glutamatergic synapse, glycine and D-serine are obligatory co-agonists at
NMDA (N-methyl-D-aspartate)-type glutamate receptors. The binding of glycine to the
NMDA receptors is a pre-requisite for NMDA receptor activation by L-glutamate
(Wolosker, 2007). In 1987, it was first demonstrated that glycine facilitated the excitatory
transmission through the activation of the NMDA receptor. Johnson and Ascher
performed experiments on primary cortical neuron cultures where these cells showed a
stronger response to glutamate of NMDA when glycine was present (Johnson and
Ascher, 1987). The ionotropic NMDA receptor is a ligand-gated Ca++ channel (Jewett
and Thapa, 2018). This receptor is particularly important because it participates in a
wide range of functions such as long-term potentiation, synaptic plasticity, learning and
memory (Wilard and Koochekpour, 2013).

1. 3. 2 Glycine Transporters
Glycine transporters are endogenous regulators of glycine by controlling its
extracellular levels at inhibitory and excitatory synapses (Harvey and Yee, 2013). They
terminate the transmission.
Glycine transporter 1 (GlyT1) and Glycine transporter 2 (GlyT2), belong to the
solute carrier 6 (SLC6) transport family. These are integral membrane-secondary active
transporters characterized by the Na+ -dependent translocation of amino acids or amino
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acid-like substrates. Other members of this family include gamma-amino butyric acid
(GABA), dopamine (DAT), serotonin (SERT), and norepinephrine (NET) transporters.
The SLC6 family has essential roles in eukaryotes where they modulate the intensity of
signals in the central and peripheral nervous system. Members of this family are directly
associated with several human disorders and diseases such as drug addiction,
schizophrenia, Parkinson’s disease, post-traumatic stress disorder, autism, attention
deficit hyperactivity disorder, and mood disorders as depression, anxiety and obsessive
compulsive disorder. For this reason, the SLC6 family are recognized as a critical target
in the discovery and development of novel therapeutics (Promad et al., 2012).
Throughout the past years, research has focused mainly on GABA, DAT, SERT and
NET transporters. Experimental studies have demonstrated the importance of these
proteins including cytoarchitecture, mechanism of function, phenotype, among others.
By contrast, it has not been the same scenario for the full characterization of glycine
transporters. Lack of highly specific antibodies and development of innovative
methodologies might be the reason for the underrepresentation of these essential
transporters. Research studies demonstrate that glycine transporters are also important
and they have been recognized as novel therapeutic targets for schizophrenia and
alcohol dependence (Harvey and Yee, 2013), regulation of pain (Dohi et al., 2009), and
epilepsy (Shen et al., 2015).

The coordinated and complementary activity of both

glycine transporters is essential for the regulation of the glycinergic neurotransmission.
Therefore,

these

transporters

are

potential

targets

for

manipulating

this

neurotransmission (Harvey and Yee, 2013). Further research studies are critical for
discovery and clinical development of novel drugs.
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Figure 1. Expression pattern of GlyT1 and GlyT2-GFP in transgenic mouse
brain.
A comparative distribution of the GlyT1 (red) and GlyT2 (green) in a sagittal section
from a transgenic mouse that expresses GFP (green fluorescent protein) under the
control of GlyT2 (Zeilhofer et al., 2005). Mouse brain sections were stained with the
corresponding antibodies. The reactivity of GlyT1 and GlyT2-GFP exhibit similar
distribution and overlaps with a high density in the caudal areas and a very low
density in the forebrain brain, whereas GlyT1 has a widespread distribution in the
forebrain. Scale bar: 1000 µm. Images reproduced with the permission of Miryam
Pando.

The glycine transporters share some similarities. These proteins share 48%
identity at the amino acid sequence (Liu et al., 1993), present in a common protein
structure with 12 transmembrane domains, and an intracellular amino and carboxylterminal (Olivares et al., 1994; Zafra et al., 1995). However, they also have their
differences. For instance, they have different distribution [Figure 2] and cellular
expression patterns in the CNS, function (Eulenburg et al., 2005) and stoichiometry
(Roux and Supplisson, 2000; Scopelliti et al, 2016).
8

The function of glycinergic neurotransmitter transporters will be described in the
following section.
Glycine transporter 1 (GlyT1)
For decades, the function of GlyT1 has been studied from different perspectives;
nevertheless, its full characterization has not been accomplished yet. In the CNS, GlyT1
is expressed at its highest concentration in the caudal areas of the brain, in the
forebrain (figure 2) and in retina. In the caudal structures, GlyT1 is expressed in glial
cells (Cubelos, 2005). It is involved in the reuptake of glycine into the presynaptic
terminal or surrounding glia cell (Bennet et al., 1974) where it is associated with the
inhibitory glycinergic neurotransmission. Previous investigations have performed
immunochemistry technologies and confirmed expression of GlyT1 in neurons and glial
cells in the forebrain areas such as the neocortex and the hippocampus (Cubelos,
2005), but not in the thalamus. This neurotransmitter transporter is also expressed in
amacrine neurons (Pow and Hendrickson, 2000) where it combines functions covered
by neuronal GlyT2 and glial GlyT1 (from caudal glycinergic synapses) (Eulenburg et al.,
2018). In the forebrain, it has also been suggested the double role of this transporter
(Zafra, et al., 1995).
Experimental evidence showed that GlyT1 is essential for mouse survival.
Studies from knockout mouse model demonstrate that the lack of GlyT1 -/- is lethal in
early postnatal life but not during perinatal life (Gomeza et al., 2003). The absence of
GlyT1 expressed on glial cells disrupts the clearance of glycine released from the
presynaptic neuron at the synaptic cleft, leading to excessive glycinergic inhibition of the
respiratory function in the brainstem (Eulenburg et al., 2010). GlyT1 is crucial for
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maintaining a low concentration of extracellular glycine levels near the excitatory
synapse. Its main role is to prevent binding and saturation of the glycine-B site on
NMDA receptors. In other words, GlyT1-mediated glycine reuptake regulates the
activation of NMDA receptor under physiological conditions.

Illustration 2. Glycine Transporter 1 topology and isoforms.
Glycine transporter 1 with its 12 transmembrane domains connected by six
extracellular and five intracellular loops. The three GlyT1-isoforms differing in the Nterminus region (1a, 1b, and 1c), and two in the C-terminus (1e and 1d). Figure
adapted from Adams et al., 1995.

In some areas of the brain, the presence of glycine transporters overlaps with the
NMDA receptors. Electrophysiological (Chen et al., 2003) and pharmacological

(Tsai

et al., 2004) experiments demonstrate that the inhibition or deletion of GlyT1 increases
the extracellular levels of glycine, thereby increasing the activation of the NMDA
receptor. NMDA activation could be beneficial for alleviating neurological disorders such
as the schizophrenia (Harvey and Yee, 2013). Individuals that have been diagnosticated
with schizophrenia present a deficit of the NMDA receptor signaling.
10

GlyT1 exist in five different isoforms; three of them, GlyT1 a, b, and c have a
different amino terminal and the other two, GlyT1 e and d, differ in their carboxyl
terminal [Illustration 2] (Eulenburg et al., 2005). These variants occur because of
alternative promoter usage, but the distribution of these different isoforms has not been
fully addressed yet (Harvey and Yee, 2013).

Glycine transporter 2 (GlyT2)
GlyT2 is expressed in the presynaptic glycinergic neurons, principally in caudal
regions of the brain such as spinal cord, brainstem and cerebellum (Jursky and Nelson,
2002). It is also present with very low levels in the forebrain [Figure 2]. GlyT2 is
essential for glycine reuptake into the presynaptic neuron, and the recycling of glycine
for vesicular release (Eulenburg et al., 2005). Through the action of GlyT2, the vesicular
amino acid transporter known as VIAAT/VGAT, can refill and store glycine. (Zafra and
Giménez, 2008).
The absence of GlyT2 leads to a deficit of glycinergic inhibition, meaning that the
disruption of GlyT2 is lethal. Experiments performed on knockout mouse reveals that
the loss of GlyT2 located at the presynaptic neuron extremely deprives the refilling of
glycine from the presynaptic vesicles and disrupts neurotransmission (Gomeza et al.,
2003). An important point to consider is that genetic defects in human-GlyT2 have
associated to cause startle disease, also known as hyperekplexia (Rees, 2006; Harvey
and Yee, 2013). This neurological disorder refers to the involuntary movement of parts
of the body triggered by a specific stimulus such as surprise, fear or acute pain among
others. The most noticeable features of reflex are closure the eyes with force,
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movement of arms and neck, and flexion of trunk, elbows, hips and knees after auditory
or tactile startling stimuli. Tthe startling stimuli can also induce responses other than
startle reflexes, such as startle-induced epilepsy (Bakker at al., 2006).

1. 4 The Forebrain
1. 4. 1 The thalamus and the Ventral posterior medial thalamic nuclei
The thalamus is an area located in the forebrain between the cerebral cortex and
the midbrain, surrounding the third ventricle. This important area is a hub of corticalsubcortical connections and a regulator of cortical activity (Giraldo-Chica and
Woodward, 2017). The thalamus was considered and referred as the relay station of the
brain between sensory organs and the cerebral cortex. Recent studies have
demonstrated that this area is involved in more functions. The thalamus plays a central
role in regulating arousal, level of awareness and activity. Malfunction and abnormal
thalamic structure have been implicated in schizophrenia and other neurological
diseases such as mood disorders (Penner et al., 2017). Damage to this area can lead to
permanent coma (Laureys et al., 2016).
A very important pathway where the thalamus is involved is the spinothalamic
tract. It is a sensory pathway from the skin, which carries information about pain,
temperature, pressure, itch, and crude touch. This pathway decussates in the spinal
cord and continues to the somatosensory areas of the thalamus (Al-Chalabi and Gupta,
2018). Then the information ascend to the cerebral cortex (Sherman, 2016).
The ventral posterior medial thalamic nuclei is a small area of the thalamus.
Temperature and pain sensations from the skin of the face, neck and oral cavity

12

(trigeminal system) are carried to the VPM. This pathway is called the trigeminothalamic
tract and is known as the trigeminal lemniscus (Anthoney, 1993).

1. 5 Overarching Goals and Aims of the Thesis
The overarching goal of this work is to identify the cells expressing the
neurotransmitter transporter GlyT1 in the mouse VPM and to characterize these cells. It
has been described that GlyT1 is mainly expressed in glial cells and only a few reports
describe that GlyT1 is also expressed in small populations of glutamatergic neurons
(Cubelos, 2005).

Based on previous experimental results, this study provides

foundation to suggest that GlyT1 is expressed in neurons in the forebrain, specifically in
the VPM.
The laboratory mouse model has been used for this study. Different mouse
strains were used since some lines have been genetically modified. These strains
allows identifying the expression of specific genes and proteins of interest. Moreover,
histological experiments and intracranial injections of fluorescent tracers provide
evidence that suggest novel concepts regarding the cell type expressing GlyT1 in the
VPM.
Experimental studies have demonstrated that inhibition of glycine transporters in
the forebrain has shown beneficial effects in patients with neurological disorders such
as schizophrenia (Chue and Baker, 2013). It has been proposed that the negative and
cognitive symptoms of schizophrenia originate from the hypo-function of the NMDA
receptors (Gray and Roth, 2007; Hashimoto, 2014; Umbricht et al., 2014). Current
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GlyT1-inhibitors have not improved completely the negative symptoms from
schizophrenia such as withdrawal and lack of motivation (Goff, 2014).
It is imperative to determine whether GlyT1 is expressed in neurons or/and glial
cells because depending on its location, it will be possible to understand the overall
kinetics of the glycinergic neurotransmission. In other words, if GlyT1 is expressed in
neurons, then it can be suggested that this protein has a similar function as GlyT2 when
this one is not present in the cell. Therefore, it could be suggested that GlyT1 would
have a dual function and mechanism in the CNS as it has been proposed in the
amacrine neurons (Eulenburg, 2018).
After understanding how glycinergic homeostasis is achieved, these insights will
be an important step towards future drug development for alleviating neurological
disorders in the thalamus and other areas of the brain.

14

Chapter 2
Materials and Methods

2.1 Animals Strains
Wild type and transgenic C57BL/6 and FVB/N strains were used for the stereotaxic
surgeries and brain collection. Animals were housed in the vivarium facility located in
the University of Texas at El Paso (UTEP) with controlled temperature, oxygen and a
12-hour light/dark cycle. Transgenic animals arrived to UTEP in the spring of 2018 from
The Jackson laboratory. Experimental procedures were conducted under Dr. Miranda’s
protocols (A-201303-1) in compliance of the UTEP Institutional Animal Care and Use
Committee (IACUC).
Table 1. Animal Strains
Strain
C57BL/6 – wild type

Age

3–4
months
FVB/N-Tg 14Mes/J
3–4
months
B6.Cg-Tg(Slc32a13–4
COP4*H134R/EYFP)8Gfng months
CB6-Tg(GAD673–4
EGFP)G42Zjh/J
months

Weight
28 – 33
grams
28 – 33
grams
28 – 33
grams
28 – 33
grams

Procedures
Stereotaxic surgery
and perfusion
Stereotaxic surgery
and perfusion
Stereotaxic surgery
and perfusion
Stereotaxic surgery
and perfusion

JAX stock #
n/a
003257
014548
007677

2.2 Stereotaxic Surgery and Tracers Injection
A group of wild type-male mice (3.5 months old) was injected unilaterally in the
VPM (Illustration 3). The Picospritzer III apparatus (Parker Hannifin Corporation,
Precision Fludics Division) and the stereotaxic injector were used to inject 100 nL of
the traces. These tracers were the retrograde tracer Fluoro-Gold (Invitrogen), the
anterograde adeno-associated viral particles expressing the reporter gene mCherry
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and GFP under control of the synapsin and the GFAP promoter (University of North
Carolina at Chapel Hill, Vector Core).
Mice were weighed, shaved and anesthetized with isoflurane, USP (Piramal
Healthcare) administered followed by inhalation. Mice were properly placed on the
mouse stereotaxic instrument (Stoelting). Eyes remained open during the time of the
surgery; therefore, lubricant eye ointment (Akorn) was applied on them to prevent
corneal drying. Surgical, utensils and solutions used for the surgery were autoclaved.
The coordinates of the site of the injection used for each animal were obtained from
the Mouse Brain atlas. According to the Paxinos and Franklin, section 46 indicates that
the VPM area is located in the following coordinates (table 5).

Table 2. Stereotaxic coordinates
Coordinates
Anterior Posterior (AP)
Medial Lateral (ML)
Dorsal Ventral (DV)

millimeters
1.79
1.50
3.50

The micro syringe was inserted into the desired area for five minutes before and
after the injection. After tracer delivery, the micro syringe and the ear bars were
removed. The open skin was sealed with mouse clips using a clip applier (Reflex 7) and
triple antibiotic ointment (Curad, Bacitracin Zinc, Neomycin Sulfate, and Polymyxin B
Sulfate) was applied on the wound. Mice were monitored for three hours right after the
surgery and received the post-procedural treatment. The post-procedure supervision
continued for the next five days as the IACUC protocol states.
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Illustration 3. Schematic representation of the injection site.
Mouse head with an incision showing the bregma and lambda lines on the skull, and
the injector on the site of injection. Coronal brain section showing the desired area of
injection (VPM in green).

2. 3 Perfusion
Animals were perfused after two weeks of the stereotactic surgery (Illustration 4).
This time allowed tracers to travel within the brain. First, the mice were deeply
anesthetized with isoflurane and they were intraperitoneal injected with a lethal dosage
of sodium pentobarbital (50 mg/ml stock) at a concentration of 80 mg/kg. Mice were
transcardially perfused (left ventricle of the heart) with about 300 mL of 0.9% saline
solution followed by 300 mL of cold 4% paraformaldehyde (Paraformaldehyde Ganular,
Electron Microscopy Sciences, Cat. No. 19210) in 1x of phosphate buffered solution
(PBS, 137 mM sodium chlorine (Sigma Aldrich, LOT No. 081M0051V), 2.7 mM
potassium chloride (Sigma Aldrich, LOT No. 077k0024), 8.1 mM sodium phosphate
dibasic (Sigma Aldrich, LOT No. 096K0141), 1.47 mM potassium phosphate monobasic
(Mallinckrodt Chemicals, LOT E18478), pH 7.4) using a peristaltic pump (MasterFlex
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console drive, Cole-Parmer Instrument Company from Dr. Kristin Gosselink’s lab). The
animals were decapitated and the brain was taken out from the skull and placed it into
50 mL of 4% PFA in 1x PBS at 4 °C. Post-fixation will be overnight followed by
cryprotection using 30% sucrose (Sigma, Lot. No. SLBP5260V) in 1x PBS for at least
24 hours at 4 °C.

Illustration 4. Schematic representation of perfusion and brain collection. Each
animal was transcardially perfused through the ventricular catheter with saline
solution followed by 4% paraformaldehyde. After removal of the brain, it was placed
in the fixative solution, followed by 30% sucrose.
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2. 4 Tissue collection
After fixation and cryoprotection of the collected brains, they were sectioned using a
Leica SM200R sliding microtome (Illustration 5). The 30 µm-thick- coronally sections
were obtained. Five adjacent sections of brain tissue series were distributed per well
in a 24 well cell culture plate (Cellstar, cat. No: 662160). They were incubated with
500 mL of antifreeze solution (6.58 sodium phosphate monobasic, 19.23 mM sodium
phosphate dibasic, 30% ethylene glycol, 20% glycerol (Sigma, Lot # BCBQ5800V)
and stored at -20 °C.

Illustration 5. Schematic representation of the brain tissue collection.
Each brain was sectioned coronally using a sliding microtome (Leica SM2000R),
starting anteriorly and continuing on the posteriorly part of the brain. Brain tissues
were stored at -20 °C in an antifreeze solution until further use.
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2. 5 Histology
2. 5. 1 Nissl Staining
Nissl staining is an imperative technique needed for the comparison of the
collected brain sections with The Mouse Brain Atlas (Paxinos and Franklin, 2012)
sections. In this way it is possible to confirm the collected sections include the region of
interest. The first part of this technique dehydrates the tissue allowing it to be
compatible with the xylenes, which remove the fat from the tissue. The second part
allows the tissue to be rehydrated making it able to stain with the thionine solution. The
Nissl stain (thionine) stains the ribosomal RNA. Finally, the tissue is dehydrated
allowing the mounting medium DPX to be compatible with the tissue. One of the five
sections previously collected was used and stained utilizing this technique.
For the Nissl staining, gelatin-coated slides were used to mount the brain tissue. In
order to coat the slides, VWR Micro slides (Fisherbrand Superfrost, Microscope Slides,
white and pre cleaned, size 25 x 75 x 0.1 mm) were used. They were subbed in 1%
Knox Original Gelatin Unflavored (Kraft Foods Global INC) and chromium potassium
sulfate (Acros Organics, Lot: A0343854) solution in water at 45 oC for 5 minutes. The
slides were placed into the oven at 65 oC for 48 hours to let them dry. In the meantime,
the solutions were prepared and poured into small containers. Therefore, reagent
alcohol for histological grade (Fisher Chemical, A962P-4, LOT 165021) was diluted in
deionized water at increasing concentrations: 50%, 70%, 95%, 95%, 95%, 100%,
100%, 100%. Xylenes for histological grade (Fisher Chemical, X3P-1GAL, LOT 165460)
were used at 100% for two containers (xylenes 1 and xylenes 2) (Illustration 6). The
Nissl stain was prepared with 5.84% glacial acetic acid (Sigma Aldrich, L
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OT 04896DMV), 1 M sodium hydroxide, and 0.5% Thionine acetate salt (Sigma, LOT
No. BCBR1862V). The solution was filtered and stored in the dark at 65 oC. Once the
slides, solutions and stain were ready to use them, the tissue was mounted. The
following day, the slides with the tissues were passed through the Nissl procedure as
shown in Table 2. Slides with brain tissue sections and with no residuals, were poured
with 300 µL of DPX Mountant for histology (Sigma, Lot # BCBH3443V). Coverslips
(Fisherbrand, Microscope Cover Glass, size 24 x 60 mm) were used to seal the slides.
In order to analyze the brain sections, pictures were taken in the microscope and
compared with The Mouse Brain Atlas (Paxinos and Franklin, 2012). As a result, each
section was assigned to a corresponding atlas level.

Table 2. Nissl Procedure
Duration

Solution

3 minutes per solution

DI Water, 50%, 70%, 95%, 95%, 100%,100% 100% EtOH

5 minutes

Xylenes 1

30 minutes

Xylenes 2

2 minutes per solution

Xylenes 1, 100%, 100%, 100%, 95%, 95%, 70%, 50%
EtOH, DI Water

15 dips

Nissl Stain: Thionine

20 dips

DI Water, 50%, 70% EtOH

3 minutes per solution

95%, 95%, 100%, 100%, 100% EtOH, xylenes 1, xylenes 2
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A)

B)

Illustration 6. Nissl Staining Procedure.
Schematic representation of A) the pink tissue symbolizes the tissue before the
staining process and the purple tissue represents the appearance of the section after
the Nissl staining. B) Each color box represents the order of the solutions in this
technique.
2. 5. 2 Tissue Immunofluorescence
The

sections

that

have

the

areas

of

interest

were

used

for

immunohistochemistry. First, the desired tissue was transferred into a net well plate
filled with 1X TBS. Five washes with 1X for five minutes each were required. The plate
was on the belly dancer with a speed of four at room temperature. Tissues were
transferred to a new 24- well plate. They were incubated for two hours with 300 µL of
blocking solution (2% normal goat serum, 0.1% triton (Triton X-100, Sigma. Lot #
031M0301V), 1X TBS)) per section. The sections were transferred to a new well with
300 µL of primary antibody (see table 3) depending on the protein of interest and diluted
in blocking solution. This incubation took place on the belly dancer in the cold room
(4°C) for 18 to 24 hours. The plate was covered with aluminum foil to prevent
evaporation of the solutions. Prior to and after the incubation with the specific secondary
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antibody, washes for five times with 1X TBS for five minutes were done. The required
secondary antibody (see table 4) was diluted in 1X TBS. Brain sections were incubated
for two hours at room temperature and in the dark. The plate was covered with
aluminum foil, but this time to prevent quenching of the fluorescent dye. Lastly, sections
were mounted on a normal glass slide (VWR Micro slides Fisherbrand Superfrost,
Microscope Slides, white a precleaned, size 25 x 75 x 0.1 mm). A petri dish was filled
with 1X TBS and the tissue was placed into the buffer. A fine paintbrush was used for
tissue handling and to guide it on the glass slide. After the tissues were onto the slide,
300 µL of sodium bicarbonate glycerol (0.1 M NaHCO3, pH 8.62) were poured on top.
The slide was covered with the coverslip (Fisherbrand, Microscope Cover Glass, size
24 x 60 mm). Clear nail polish was used to seal the edges of the slide and to prevent
any tissue damage. Slides were kept overnight in the dark at room temperature, and
then stored at 4°C. Finally, slides were ready to be analyzed by the fluorescent and
confocal microscope.

Table 3. Primary Antibodies
Reagent
GlyT1
Mouse Anti-MAP2 a&b
Monoclonal antibody
Mouse X Neuronal Nuclei
(NeUN)
Purified Mouse Anti-rat TAU
Mouse monoclonal (GF5) to
GFAP (Glial Fibrillary Acidic
Protein)

Host
Species

Dilution

Source

Lot
Number

Rabbit

1:500

Dr. Manuel
Miranda

In house

Mouse

1:500

Millipore

LV1486527

Mouse

1:500

Millipore

NG1876252

Mouse

1:1000

BD

12951

Mouse

1:500

Abcam

Ab10062
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Table 4. Secondary Antibodies
Reagent
Alexa 488 – conjugated
AffiniPure Donkey Anti-mouse
igG
Alexa 488 – conjugated
AffiniPure Donkey Anti-Rabbit
igG

AntiSpecies

Dilution

Mouse

1:2500

Rabbit

1:2000

Cy3 – conjugated AffiniPure
Donkey Anti-Mouse igG

Mouse

1:2000

Cy3 – conjugated AffiniPure
Donkey Anti-Rabbit igG

Rabbit

1:2000

Source
Jackson
ImmunoResearch
Laboratories
Jackson
ImmunoResearch
Laboratories
Jackson
ImmunoResearch
Laboratories
Jackson
ImmunoResearch
Laboratories

Lot
Number
104332

126883

124774

76381

2. 6 Microscopy and Confocal Microscopy Analysis
Nissl images were taken using a Zeiss Microscope, AxioCam MRm, software
AxioVision Rel. 4.8, (SN: 3834002557), 10X objective, white light and MosaiX
command. The brain sections were analyzed using a fluorescent microscope and a
confocal microscope. The required filter sets of DAPI, Alexa 488, and Cy3 were used to
visualize the fluorescent dyes in the mouse brain tissue. High-resolution digital
fluorescent images were captured using a Zeiss LSM 700 confocal microscope
(Cytometry, Screening and Imaging Core Facility). The microscope is equipped with a
40 and 63 immersion oil objective. ZEN 2009 software (Zeiss, New York, NY) was used
for acquisition and processing of confocal images. Single-plane images were
sequentially scanned using specific settings for each channel and acquired at the
highest pixel resolution. The same software was used to visualize localization of the red
and green signals from the stained neural tissue.
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Chapter 3
Results

3.1 GlyT1 and GlyT2-GFP Distribution in the Forebrain
The immunoreactivity of GlyT1 and GlyT2-GFP exhibit different distribution
throughout the forebrain (figure 2). GlyT1 has a widespread distribution throughout the
thalamus, whereas GlyT2 is present only in areas such as the paraventricular thalamic
nucleus and the optic tract. The distribution of GlyT1 and GlyT2 overlaps with a higher
concentration in some areas of the forebrain such as the lateral habenular nucleus
medial and lateral part, the central thalamic nucleus, the medial thalamic nucleus, and

Figure 2. Expression pattern of GlyT2-GFP and GlyT1 in the mouse forebrain.
A comparative distribution of the patters of the GlyT1 (red) and GlyT2 (green) in a
coronal section from a transgenic mouse that expresses GFP under the control of
GlyT2 (Zeilhofer et al., 2005). Scale bar: 1000 µm.
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the dorsal and lateral zona incerta. The distribution of both transporters overlaps with a
lower concentration in the posterior thalamic nuclear group, dorsal hypothalamic area
and in the nigrostriatal tract. It is worth mentioning that neither GlyT1 nor GlyT2 are
present in the external medullary latima, mammillothalamic tract and cerebral peduncle.
GlyT1 is highly expressed and well distributed in the VPM. Even though there are many
other areas of the mouse brain that have been labeled with GlyT1, this study focuses in
the VPM. This area attracted our attention because of the high density of glycinergic
fibers and the ease of analysis. These results might suggest that GlyT1 has a different
role and may be located and function in putative glycinergic fibers in the VPM .

3. 2 GlyT1 and Neuronal Markers

After finding the expression of GlyT1 in a such important area of the thalamus, it
was not clear whether neurons or glial cells express this transporter.

Therefore,

neuronal and glial biomakers along with the highly-specific GlyT1 antibody were used to
identify the cell type expressing GlyT1 by histological techniques.
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Figure 3. GlyT1 and TAU immunoreactivity in a coronal section of the mouse
thalamus.
Immunoreactivity from GlyT1 (green) and TAU (red) in the thalamus. Encircled
region represents the VPM area. Both proteins of interest are highly expressed in the
VPM. Nissl image represents figure 46 from The Mouse Brain Atlas (Paxinos and
Franklins, 2012). Scale bar: 200 µm

The antibodies TAU, MAP2 and NeuN were used as neuronal markers. The target
proteins of interest are microtubule-associated protein tau (TAU), microtubuleassociated protein 2 (MAP2), and neuronal nuclei (NeuN). Axons and dendrites contain
microtubules

and

microtubule-associated

proteins

(MAPs)

with

characteristic

structures. Among MAPs, MAP2 is specifically expressed in dendrites whereas tau
proteins are abundant in the axons (Chen, 1992). Both proteins are also expressed in
cell bodies. In figure 3, both proteins of interest, TAU in red and GlyT1 in green are
expressed in the VPM. The VPM at a higher magnification (figure 4) allows visualizing
the immunoreactivity from both proteins in a detailed way.

27

Moreover, the immunofluorescence labeling of TAU aids to identify the cell type
expressing GlyT1. In figure 4 (panel A-C), the white arrows indicate the neurons that are
surrounded by the GlyT1 immunoreactivity.

A)

B)

C)

Figure 4. Immunofluorescence labeling GlyT1 and TAU proteins in the
VPM. Confocal images from the VPM stained with GlyT1 (green) and TAU
(red) antibodies. White arrows in (A, B and C) represent the neurons labeled
with TAU and surrounded by GlyT1. (B) In the higher-magnification image
from (A), the TAU expression surrounded by the GlyT1 is observed in a
detailed manner. Scale bar: (A) 20 and (B) 10 µm.
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The MAP2 and NeuN cell markers were used to confirm the findings of the GlyT1
and TAU immunoreactivy in the same cell. MAP2 (figure 5) and NeuN (figure 7)
antibodies were successfully expressed in the thalamus. Images at a higher
magnification from both sections, indeed, confirm the expression of GlyT1 in neurons
labeled with MAP2 (figure 6) and NeuN (figure 8).

Figure 5. GlyT1 and MAP2 immunoreactivity in a coronal section of the mouse
thalamus.
Immunoreactivity from GlyT1 (green) and MAP2 (red) in the thalamus. Encircled
region represents the VPM area. Both proteins of interest are highly expressed in the
VPM. Nissl image represents figure 46 from The Mouse Brain Atlas (Paxinos and
Franklins, 2012). Scale bar: 200 µm.
Higher magnification images from GlyT1 and MAP2 immunoreactivity (figure 6)
allow visualizing more cells bodies labeled compared to the dendrites of the cell.
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A)

B)

C)

Figure 6. Immunofluorescence labeling GlyT1 and MAP2 in the VPM.
Confocal images from the VPM stained with GlyT1 (green) and MAP2 (red)
antibodies. White arrows in the merge figure of (A) and (B) show the neurons
labeled by MAP2 and expressing GlyT1. (C) A single neuron where its dendrites
and cell bod are labeled with MAP2 and co-localizing with GlyT1. Scale bar: (A)
and (B) 20 µm and (C) 10 µm.

A reason of the partial absence of the stained dendrites could be that the section
is not thick enough to show the complete neuron. However, in panel C it is possible to
observe a single neuron labeled with MAP2 and the GlyT1 expression by the plasma
membrane of the cell.
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The neuronal biomarker NeuN was also used to confirm the cell type expressing
GlyT1 (figure 7). As expected, neurons stained with NeuN also express GlyT1 (figure
8).

GlyT1

NeuN

Merge

Nissl

Figure 7. GlyT1 and NeuN immunoreactivity in a coronal section of the mouse
thalamus
Immunoreactivity from GlyT1 (red) and NeuN (green) in the thalamus. Encircled
region represents the VPM area. Nissl image represents figure 46 from The Mouse
Brain Atlas (Paxinos and Franklins, 2012). Scale bar: 200 µm.
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GlyT1

NeuN

Merge

Figure 8. Neuron cells stained with NeuN express GlyT1.
Confocal images from the immunofluorescence labeling GlyT1 (red) and NeuN
(green) in the VPM. White arrows in the merge figure depict the neurons with their
stained nucleus and expressing GlyT1. Scale bar: 20 µm.

3.3 GlyT1 and Glial Marker
Glial cells are essential for neuronal function and viability such as structural
support, neurotransmitter removal, glial scar formation and metabolic support to
neurons (Nishiyama et al., 2005). These cells are further involved in the formation and
stabilization of synapses and the modulation of synaptic efficacy (Doetsch, 2003).
Astrocytes are stellate cells that contain glial fibrillary acidic protein, the molecule
constituent of glial filaments (Eng, Ghirnikar. and Lee, 200). The astrocyte-specific glial
fibrillary acidic protein (GFAP) antibody served as a glial marker that allowed the
identification of the glial cells through the brain tissue.
This antibody was used for labeling the glial cells thought the thalamus (figure 9).
Although the major glial types expressed in the CNS are astrocytes and
oligodendrocytes (Jessen, 2004), the thalamus has not been stained with the GFAP
antibody. This might be because of several reasons. One of them is because the
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antibody is not as specific as expected or the protocol is not the optimal for the antibody
incubation.

Figure 9. GlyT1 and GFAP immunoreactivity in a coronal section of the
mouse thalamus.
Immunoreactivity from GFAP (green) and GlyT1 (red antibodies. GFAP is not highly
expressed in the VPM as it is in dorsal areas of the thalamus. Encircled region
represents the VPM. Nissl image represents figure 44 from The Mouse Brain Atlas
(Paxinos and Franklins, 2012). Scale bar: 200 µm.
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A higher magnification of immunoreactivity from GFAP in the VPM (figure 10),
show a small population of glial cells labeled with the antibody. However, the single cell
is excluded from GlyT1 immunoreactivity. Based on these findings, we can suggest that
GlyT1 is not expressed in astrocytes. However, further immunohistochemical
experiments and evidence will have a solid answer whether GlyT1 is expressed in other
glial cells (such as microglia) or it is only expressed in neurons.

A)

B)

Figure 10. Glial cells are devoid of GlyT1 immunoreactivity in the VPM.
Confocal images from the VPM stained with GlyT1 (green) and GFAP (red)
antibodies. (A) GlyT1 do not co-localize with GFAP in the VPM, (B) shows a highermagnification from figure (A), where shows that the single glial cell is not surrounded
by GlyT1. Scale bar: (A) 50 µm and (B) 20 µm.
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3.4 Stereotaxic Surgeries and Injection of Fluorescent Tracers
GlyT1 and Fluoro-Gold
To better visualize and confirm the previous results, In vivo intracranial injections
on mice were performed. Three different tracers were used for this study. The
retrograde tracer

A

FG injection

B

GlyT1

FG

Merge

Figure 11. Fluoro-Gold injection delivered into the mouse thalamus and GlyT1
immunoreactivity. (A) The injection site of the tracer into the VPM. The site of the
injections is enclosed by the yellow square, whereas the enclosed region represents
the VPM. Nissl image from the coronal section represents level 52 from The Mouse
Brain Atlas (Paxinos and Franklins, 2012). (B) Confocal images from the VPM
stained with GlyT1 (red) and FG (yellow). Arrows show the neurons expressing
GlyT1. Scale bar: (A) 500 µm and (B) 50 µm.
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Fluoro-Gold (Figure 11- A) and adeno-associated viral (AAV) particles that express the
mCherry protein under the promoter of synapsin (Figure 12- A) and GFAP.
Retrograde tracers traced neural connections from their synapse to their cell
body. In contrast, anterograde tracers traced axonal projections from the cell body to
the synapse (Purves, 2008).

GlyT1 and Neuronal Fluorescent Tracer
Tissues from these brain injections were stained with the GlyT1 antibody in order
to observe the transporter and learn whether it is express in neurons or glial cells.
As shown in figure 12-A, the injection site of the AAV particles was into the VPM
and the particles were deposited in this region. Higher resolutions images from figure
12-B and 12-C show that GlyT1 staining of mCherry-expressing tissue demonstrate that
GlyT1 is expressed in neurons (white arrows). Indeed in figure 12-C, it is possible to
observe the co-location of GlyT1 in the cytoplasmic membrane of the labeled-neuron.
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A

AAV-Syn injection

B GlyT

AAV-Syn

Merge

C GlyT1

AAVSyn

Merge

1

Figure 12. AAV particles delivered into the VPM and labeled with GlyT1. (A)
Injection site of the AAV- synapsin. The site of the viral particles concentration is
surrounded by the square, whereas the enclosed region represents the VPM. Nissl
image represents level 45 from The Mouse Brain Atlas (Paxinos and Franklins,
2012). (B, C) Confocal images from the immunostaining with GlyT1 (green). Arrows
show the neurons that express mCherry under the synapsin promoter and also
GlyT1. Scale bar: (A) 500 µm (B) 20 µm and (C) 10 µm.
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GlyT1 and Glial Fluorescent Tracer
Moreover, the AAV expressing the reporter gene GFP under GFAP promoter
was delivered into the same manner as the neuronal tracers in the VPM (Figure 13 – A).
These viral-fluorescent particles were used as a glial marker. It was expected glial cells
were going to encode and express the GFP protein. Using the GFAP antibody along the
tracing aimed to identify
and confirm whether these viral particles were expressed as expected. Unfortunately,

A GFAP-GFP
injection

B GlyT1

GFAP

GFAP-GFP

Merge

Figure 13. Glial fluorescent tracer is not expressed in all glial cells.
(A) Injection site of the glial tracer (green). The site of the viral particles
concentration is surrounded by the square and the enclosed region represents the
VPM. Nissl image represents level 46 from The Mouse Brain Atlas (Paxinos and
Franklins, 2012). (B) histology experiment stained with GlyT1 (red) and the glial
antibody GFAP (blue) along the glial tracer GFP-GFAP. The glial tracer does not colocalize with the antibody and is over expressed in the cells. Scale bar (A) 500 µm
(B) 20 µm.
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when the high-resolution images were taken under the confocal microscope it was
possible to observe the GFAP antibody and the glial tracer did not co-localize and the
fluorescent tracer was overexpressed in the infected cells. As a result, this brain tissue
could not reveal either suggest clearly whether GlyT1 is also expressed in glial cells
besides neurons in the VPM. However, if the fluorescent tracers is excluded and only
the GFAP antibody is taking into account, it is possible to suggest that GlyT1 is
excluded from glial cells.

3.5 Transgenic Brain Tissue
Brain tissues obtained from the transgenic mice were stained with the GlyT1
antibody to detect its presence throughout the thalamus. These sections expressed
specific fluorescence protein on the tissue depending on their strain. Three different
strains of transgenic mice were used for this study: FVB/N-Tg 14Mes/J, B6.CgTg(Slc32a1-COP4*H134R/EYFP)8Gfng/, and CB6-Tg(GAD67-EGFP) G42Z -jh/J. The
green fluorescent protein (GFP) is expressed under the control of the GFAP, VGAT and
GAD67 promoters, respectively.

GlyT1 and GFAP-GFP
The strain FVB/N-Tg 14Mes/J expresses GFP under the control of the astrocytespecific glial fibrillary acidic protein (GFAP) promoter. Brain tissue from these animals
were used with the purpose of confirming our previous findings where the monoclonal
GFAP antibody was used. However, only a small portion of glial cells were identified in
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the VPM (figure 14) and transduced cells showed high expression of GFP, preventing
the observation of cells by microscopy.

GlyT1

GFAP-GFP

Merge

Figure 14. GFAP-GFP brain tissue from a transgenic mouse and GlyT1 staining.
Histology experiment stained with GlyT1 (red) in brain tissue from a transgenic
mouse, which express GFP under the glial promoter (green). A small portion of glial
cells is expressed in the VPM (depicted in the merge figure). This section represents
level 48 from The Mouse Brain Atlas (Paxinos and Franklins, 2012) (not shown).
Scale bar is 200 µm.

GlyT1 and VGAT-GFP
On the other hand, our ultimate goal was to characterize the neurons expressing
GlyT1 and learn whether GABA and GlyT1 markers were located in the same cell.
Therefore, two transgenic mouse lines were used, the VGAT and GAD67 lines that use
the corresponding promoters to express the reporter protein GFP. The

B6.Cg-

Tg(Slc32a1-COP4*H134R/EYFP)8Gfng/J expresses GFP under the control of the
vesicular GABA transporter (VGAT or Slc32a1) promoter. VGAT is specifically
expressed in GABAergic and glycinergic neurons (Gasnier, 2000). VGAT is highly
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GlyT1

VGAT-GFP

Merge

Figure 15. VGAT-GFP transgenic mouse does not express VGAT in all the
thalamus. Histology experiment stained with GlyT1 (red) in brain tissue from a
transgenic mouse, which express GFP under the vesicular GABA transporter, VGAT
(green). The greatest population of glutamatergic cells are expressed in the lateral
margin of the ventricular surface of the thalamus. This section represents level 48
from The Mouse Brain Atlas (Paxinos and Franklins, 2012) (not shown). Scale bar is
200 µm.

concentrated in the nerve endings of GABAergic neurons in the brain and spinal cord
but also in glycinergic nerve endings (Legendre, 2001). GABA is an inhibitory
neurotransmitter that was studied before discovering glycine. Glycine and GABA
mediate inhibitory neurotransmission in the spinal cord and in different areas in the
central nervous system (Muller et al., 2008). The co-release of both neurotransmitters
by the same presynaptic terminal was first described in cerebellar Golgi cells, in the
spinal cord and in the superior olivary complex (Buras et al., 2015). This mouse line was
used to look for the presence of GlyT1 in the VPM. In figure 15, it is possible to observe
that VGAT is expressed in the lateral margin of the ventricular surface of the thalamus
and not in all areas. However, higher-resolution image from the tissue stained with
GlyT1 was not taken because the VGAT expression
was completely absent from the area of interest.
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GlyT1 and GABA-GFP
The strain CB6-Tg(GAD67-EGFP)G42Zjh/J also known as the G42 line,
expresses GFP under the control of the GAD67 promoter.

The glutamic acid

decarboxylase (GAD) is an enzyme required for the conversion of L-glutamate to GABA
and only labels pre-synaptic neurons producing GABA. This transgenic mouse tissue
was used as another way to see if the presence of GlyT1 in the VPM.

GlyT1

GAD67-GFP

Merge

Figure 16. GAD67-GFP transgenic mouse and GlyT1 staining. Histology
experiment stained with GlyT1 (red) in brain tissue from a transgenic mouse, which
express GFP under the glutamic acid decarboxylase, GAD 67 (green).
Glutamatergic neurons are well expressed in the dorsal and lateral margins of the
thalamus. This section represents level 46 from The Mouse Brain Atlas (Paxinos and
Franklins, 2012) (not shown). Scale bar is 200 µm.
20 µm.
In figure 16, the expression of GAD67 is more abundant in the thalamus
compared to the VGAT-reactivity from the transgenic mouse tissue. GAD67 is highly
expressed in areas of the thalamus such as the dorsal lateral geniculate nucleus (DLG)
and the lateral posterior thalamic nucleus (LPLR). Both nuclei are important for the
visual pathway; meanwhile the DLG is a relay center in the thalamus which It receives a
major sensory input from the retina. GAD67 is also present in the VPM but not as much
as the previous areas (figure 16). Indeed, GAD67 and GlyT1 do not show co-expression
from the same neuron in the VPM (figure 17- A), but they might be shared by a small
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number of neurons in the DLG (Figure 17- B). The white arrow depicts a neuron that
has been labeled with VGAT and GlyT1.

A GlyT1

GAD67-GFP

Merge

B

GAD67-GFP

Merge

GlyT1

Figure 17. GAD67-GFP transgenic mouse does not express GAD67 in all the
thalamus. Confocal images from the immunostaining with GlyT1 (red) along the
GAD6 expression (green). (A) GAD67 is partially expressed in the VPM and does
not co-localize with GlyT1, whereas it does in the (B) dorsal lateral geniculate
nucleus and the neuron is represented with the white arrow. Scale bar: (A, B) 20
µm.20 µm.
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Chapter 4
Discussion and Future Directions

4.1 Discussion
The major goal of this research study was to elucidate the identification of the cell
type expressing GlyT1 and to characterize these cells. To answer this question, we
performed different approaches to differentiate whether this neurotransmitter transporter
is expressed by neurons or glial cells. These approaches include
immunohistochemistry, intracranial injections of retrograde and anterograde tracers and
transgenic mice models.
The thalamus is an important area of the brain, which is involved in sensory and
motor signal relay. We observed that this region is enriched in GlyT1 and not in GlyT2.
It is interesting that the role of GlyT1 has been well studied in areas of the brain where
GlyT1 and GlyT2 are co-expressed; since both are required for the glycine
homeostasis. However, in areas of the brain where GlyT1 is expressed, it is suggested
that it plays an important role for the NMDA receptor function. Research studies
describe that GlyT1 is expressed mainly in glial cells in the caudal regions of the brain,
but the cell expression GlyT1 in the forebrain is poorly understood. To determine the
identification of the cell type, we stained brain sections of mouse and used different
neuronal and glial markers. Interestingly, we found that GlyT1 is located in neurons and
it appears always surrounding the expression of a cytosolic protein; by contrast, we did
not see glial cells expressing GlyT1.

44

The intracranial injections of the fluorescent tracers and the AAV particles were
delivered into the VPM, where GlyT1 is highly expressed. The accumulation of the
fluorescent particles were deposited on neurons or glial cells. The results gathered from
the neuronal tracers show a clear view where the cells bodies are surrounded by GlyT1
immunoreactivity. However, although the glial tracer was delivered and the particles
were deposited in the VPM, it did not provide a clear view of the dye in the cells. Hence,
these sections were not carried out by GlyT1 immunofluorescence because of the lack
of the GFAP-specificity.
In addition, we wanted to study if the neurons expressing GlyT1 were also
GABAergic. GAD and VGAT are essential components of GABAergic neurons and the
neurotransmitter GABA is present in the thalamus. It is worth mentioning that brain
tissue from the transgenic mice was expected to show more GFP expression
throughout the brain. Hence, we cannot conclude that the cells expressing GlyT1 are
GABAergic neurons because of the lack of expression. A possible cause from these
enigmatic features could be due to the different isoforms that characterize the VGAT
and GAD67 proteins. Another possible reason of the absence of both GABAergic
proteins in the tissue can be that these mice only express neuronal populations in
restricted areas of the brain.

4.2 Future Directions
Future studies should confirm the presence of neurons expressing GlyT1 in
GABAergic neurons. This can be accomplish using additional cellular markers targeting
neuronal cytoskeleton or cell membrane to verify the presence of the cytoplasmic
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GlyT1. Moreover, additional and different astrocytic cell markers should be used in
order to add or exclude the presence of GlyT1 in these cells.
In additional experiments, using viral injections for the transfection of neuronal
cells expressing the GlyT1 transporter would be an ultimate project to detect both,
neurons and GlyT1, in a very precise way.
Moreover, it will be important to further clarify whether the neurons that express
GlyT1 represent a new subtype of glycinergic neuron.
Furthermore, additional studies will increase the understanding of a role for
GlyT1 in neurons. For this objective, optogenetics would help to elucidate the function of
glycinergic neurons in the thalamus.
The knowledge obtained from this study will advance our understanding of the
importance of the glycinergic homeostasis in the CNS.
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